[Ip-health] New York Times: Curing Hepatitis C, in an Experiment the Size of Egypt

Thiru Balasubramaniam thiru at keionline.org
Tue Dec 15 20:20:38 PST 2015


http://www.nytimes.com/2015/12/16/health/hepatitis-c-treatment-egypt.html

Curing Hepatitis C, in an
Experiment the Size of Egypt

A new approach tested in Egypt could become the blueprint for providing
cutting-edge medicines to the poor.

By DONALD G. McNEIL Jr.DEC. 15, 2015


SHABAS EL SHUHADA, Egypt — Abdel Gawad Ellabbad knows exactly how he was
infected with hepatitis C.

As a schoolboy in this Nile Delta rice-farming village, his class marched
to the local clinic every month for injections against schistosomiasis, a
parasitic disease spread by water snails.

A nurse would boil the syringes, fill each with five doses and then jab
five boys in a row with a single needle.

“I didn’t want that hot needle touching me, so I thought I’d be smart,” Mr.
Ellabbad, 52, said. “I let the other guys go first.”

Six million Egyptians were infected with hepatitis C by unsterile needles
during the country’s decades-long fight against schistosomiasis. The virus
spread insidiously; today, at least 10 percent of Egyptians, nearly nine
million people, are chronically infected, the highest rate in the world.

But a grand experiment unfolding across the country may change all that.

Once demonized for withholding lifesaving AIDS drugs from poor countries in
Africa, chastened pharmaceutical companies are testing an alternative
strategy: a complicated deal to sell hepatitis drugs at a fraction of their
usual cost while imposing tight restrictions intended to protect lucrative
markets in the West.

The strategy has raised howls of outrage from public health advocates in
some quarters. If it succeeds, though, the arrangement in Egypt may serve
as a blueprint not just for curing hepatitis around the world, but also for
providing other cutting-edge medicines to citizens in poor countries who
could never afford them.

The experiment here is about a year old and, while still fragile, appears
to be headed for success.

Mr. Ellabbad, for one, was finally cured of hepatitis this spring. An
air-conditioning repairman, he took a three-month regimen that included
sofosbuvir, first of the new generation of miracle drugs. The pills would
have cost more than $84,000 in the United States.

He got them free from the Egyptian government, which paid about $900.

“Before, I felt like I was dying,” he said. “Now I feel like I’ve never
felt before. Like I’m 35 again.”

A Worldwide Problem

Hepatitis C is a global crisis: About 150 million people are chronically
infected, four times as many as have H.I.V., and about 500,000 die each
year of its complications, particularly cirrhosis and liver cancer.

The virus is a resilient foe. Usually transmitted by contact with blood,
hepatitis C may not cause symptoms for years. Some patients clear the
infection on their own, but in most, it becomes chronic, slowly damaging
the liver over time.

Nowhere is the virus more entrenched than in Egypt. There are an estimated
150,000 new infections each year, caused by reuse of disposable syringes,
accidental needle sticks, tainted medical equipment, and even the sharing
of nail clippers and toothbrushes among family members.

Each infected Egyptian passes the virus to three others on average, said
Dr. Manal Hamdy El-Sayed, who directs the national hepatitis-awareness
campaign. Egypt’s National Liver Institute runs 50 treatment centers and
consumes a third of the national health budget.

Fear of the virus is pervasive.

Sherif Mechawy, a barber in an upper-class neighborhood of Cairo, pumps
sanitizer on his hands and holds up a clear plastic package containing a
comb and a disposable razor for each client.

“They have to see me open it with their naked eyes,” said Mr. Mechawy, 39.
About a quarter of his customers prefer to bring their own clippers and
scissors.

For full shaves, he wears latex gloves. The hepatitis virus can survive two
days or more on a surface, and Mr. Mechawy knows even the groove where the
razor fits in the holder is dangerous.

Even harder hit than Cairo are the villages of the Nile Delta, where half
of all men older than 50 are infected.

Mohamed Khafagy, a tour guide from a rice-farming village, said every
family he knew had lost someone to hepatitis C.Liver disease killed his
father, two uncles and a cousin.

Mr. Khafagy, 39, is infected, too, and has developed Stage 3 fibrosis,
which in a wealthier country would prompt rapid treatment.

He knows that drugs to cure his infection are trickling into the country
from the West. But the nearest government clinic, in Kafr el-Sheikh, has a
three-month wait for appointments.

“Will I last that long?” he wondered aloud.

A Game-Changing Drug

For a poor country, Egypt has a relatively effective health care system,
including legions of liver specialists. Committed to repairing the damage
done by the schistosomiasis campaign, the health ministry in 2007 developed
an ambitious national hepatitis treatment plan using two old drugs:
interferon and ribavirin.

The drugs are loaded with side effects and difficult to tolerate. Last
year, Gilead Sciences, based in California, offered an alternative.

The company makes sofosbuvir, which since 2013 has been sold in the United
States as Sovaldi for about $1,000 per one-a-day pill. A course of the
drug, taken with ribavirin and often interferon, usually cures hepatitis C
infection in 12 weeks.

Sofosbuvir is an enormous blockbuster; in its first year on the market, the
drug earned Gilead more than $10 billion.

But for the past year, Gilead has sold the drug to the Egyptian government
for about $10 a pill. The government distributes it to pharmacies across
the country, where it is dispensed free to patients.

Gilead also allows 11 Indian and two Egyptian companies to make sofosbuvir
under license and to sell it at any price they like, in return for a 7
percent royalty.

Gilead was under some pressure to make the drug more widely available.
Egypt’s patent office rejected the company’s application, making it
inevitable that generic versions would eventually be sold there, said Dr.
Wahid Doss, the chairman of the National Committee for Control of Viral
Hepatitis.

In return for selling sofosbuvir cheaply, Gilead asked that Egypt impose
strict restrictions on every bottle to prevent the drug from being sold on
the black market and undermining its business elsewhere.

All pills must be dispensed by government pharmacies, for example, and all
patients must turn in an old bottle to get a fresh one. Those receiving new
bottles must immediately unscrew the cap, break the seal and take the first
pill in front of the pharmacist — making it nearly impossible to resell the
bottle.

Those restrictions infuriated international activists pushing for greater
access to medicines, who saw them as violations of patients’ rights.

Heba Wanis, a pharmacist who until recently worked at the Egyptian
Initiative on Personal Rights, said she found the requirement to take a
dose in front of the pharmacist “humiliating” and felt it “raised a lot of
ethical issues.”

Dr. Jennifer Cohn, medical director of the drug access campaign at Doctors
Without Borders, described the requirements as “a third party introduced
into the doctor-patient relationship.” Giving a drug company control over
who receives its products sets “an incredibly dangerous precedent,” she
said.

But so far, no outrage is visible on the streets.

“I agree with this completely,” said Mr. Ellabbad, the air-conditioning
repairman. “I’m a poor man. If I did not have to hand in the bottle each
time, I might have sold them to buy my son a house.”

Egypt’s health officials also say that the deal is fair.

“We don’t have a problem with the rules,” said Dr. Gamal Esmat, a liver
specialist at Cairo University Medical School and a co-author of the
national hepatitis plan. “They are to prevent the black market from moving
it to other countries.”

“If you can solve the hepatitis problem in Egypt, you are a hero,” he
added. “The drug companies know that.”

The Egyptian government’s ambitious goals are to treat 300,000 hepatitis
patients a year starting in 2016 and to drive the national infection rate
below 2 percent by 2025.

The first year was successful: A total of 125,000 patients have been
treated with sofosbuvir. Now that licensed generic versions are available
for as little as $4 a pill, Egypt is even phasing out purchases from Gilead.

Instead, the company’s next-generation product, Harvoni, a
sofosbuvir-ledipasvir combination that cures with no need for interferon or
ribavirin, is being tested for rollout in December at about $14 a day.

Already, the arrangement that Gilead struck with the Egyptian government
has been emulated by other pharmaceutical companies.

In August, the government announced that it would import a rival three-drug
combination named Viekira from AbbVie. Like Gilead, AbbVie offered the
pills at about 1 percent of the price in the United States, or about $13 a
day. In a further anti-resale measure, AbbVie renamed it Qurevo for the
Egyptian market.

In October, the government began importing Daklinza, a hepatitis drug from
Bristol-Myers Squibb.

The sudden availability of world-class hepatitis medicines has prompted
“great excitement in Egypt,” Dr. Doss said, adding, “People are getting
cured.”

Indeed, some Egyptian patients seem mystified by their good fortune.

”Do you Americans love Egyptians more than yourselves?” asked Hany Tawfik,
66, a private equity specialist who in 2014 was the first Egyptian to
receive sofosbuvir. “Why aren’t you putting pressure on Gilead to sell to
you at a reasonable price, too?”

A Drug Company Shift

For the moment, executives at the drug company, too, seem pleased with the
deal they struck. Large-scale diversion of hepatitis drugs onto the black
market has not happened in Egypt, and officials do not seem particularly
worried that it will.

“Some leakage is a given,” said Gregg H. Alton, executive vice president
for corporate and medical affairs. “Our goal isn’t to stop it 100 percent;
if we wanted that, we’d do it the draconian way and not be in the country
at all. But we do want to stop large leaks.”

In the United States and Europe, the company has been widely condemned for
price gouging. Its new hepatitis drugs are among the most costly in the
world, and the market for them is immense.

Gilead’s approach in Egypt is a radical departure, informed by the
pharmaceutical industry’s disastrous experience with AIDS drugs in Africa.

In 1997 South Africa, which had the world’s worst AIDS burden, passed a law
allowing it to suspend patents and buy generic versions of H.I.V. drugs.
Western manufacturers retaliated, closing some of their South African
plants and threatening to stop selling their new drugs there.

They went so far as to sue President Nelson Mandela, starting what former
United Nations Secretary General Kofi Annan described as a “worldwide
revolt of public opinion.” The tactic backfired.

Poor countries forced price cuts in AIDS medications by threatening to
revoke patents. The Indian generics industry emerged, and it now makes most
of the world’s H.I.V. medicines — at less than $100 per patient per year.

Those low generic prices prodded wealthy donor nations to create programs
like the Global Fund and the President’s Emergency Plan for AIDS Relief.
Now 14 million people infected with H.I.V. are receiving treatment.

In 2006, Gilead bucked the industry’s longstanding reluctance to cooperate
with Indian generics companies and gave several of them licenses to make
its best H.I.V. drug, tenofovir, for distribution in Africa in return for a
5 percent royalty.

In the nine years since, millions of Africans have taken generics
containing tenofovir, but those pills have not turned up in large amounts
in the United States or Europe. “Our worst fears did not come true,” Mr.
Alton said.

Gilead does not want to take a loss in poor countries but is willing to
help at almost no profit, he added.

But critics note that in its arrangement with Indian generics
manufacturers, the company reserved not just the richest markets for itself
but also middle-income countries like China and Russia, where an estimated
73 million people are infected with hepatitis.

Indian licensees were originally allowed to sell generic versions in only
91 of the poorest countries.

Mr. Alton acknowledged that millions of patients had been excluded from the
deal Egyptians received, but said Gilead was negotiating with their
governments and “will discount in them at rates that are realistic.”

By August, Gilead had added 10 middle-income nations to its access program,
including Brazil and Argentina, and was selling all of them Sovaldi at $10
a pill and Harvoni at about $14.

But outside activists and some Egyptian doctors worry that the current
orderly arrangements could spiral into chaos as more generics appear.

Egypt has thousands of small pharmacies that are barely regulated. Drugs
are often sold without prescriptions. Officially, the government sets
private-sector prices; in reality, the pharmacists charge what they want.

Gilead’s restrictions may have been observed by the Egyptian government,
but they will be ignored in small private pharmacies, a prominent generics
maker predicted.

“I don’t think patients will accept them,” said Sherine Helmy, the chief
executive of Pharco, a major Egyptian drugmaker. “If you are sick, and your
wife comes to buy your bottle, should the first pill be taken by your wife?”

And what happens if foreigners infected with hepatitis C in developed
countries begin to see Egypt as the place to lay hands on a fast and cheap
cure?

If an uninsured American patient “has a prescription from an Egyptian
doctor, should we stop him?” Mr. Helmy said.

“You cannot prevent people who are sick from getting medicine,” he added.
“It’s a human right.”

Asmaa El-Zohairy contributed reporting.



More information about the Ip-health mailing list